The strength of sorafenib, a Raf inhibitor, was fitted to a dataset by Melas et al.34 from HCC cell lines, which showed reductions in pMEK and pERK directly downstream of the Raf, but not much changes in pAkt after 30 min. The gene discussed is EIF2AK3; the disease is hepatocellular carcinoma.